Skip to main content
Premium Trial:

Request an Annual Quote

Unable to Secure Needed Funding, NextGen Group Likely to Wind Down Business

Premium

NextGen Group has announced that due to an inability to secure additional financing it will likely take steps to wind down its business unless it is able in the near future to find a buyer for its principal subsidiary, protein biomarker firm NextGen Sciences.

The company noted that it has not yet received any acceptable offers for NextGen Sciences and that even if it is sold, "it is unlikely that it will generate sufficient cash to settle all the company's outstanding creditors in full."

NextGen Sciences traditionally focused on providing custom biomarker services for pharma and biotech firms but over the last year moved into the plasma biomarker discovery space, developing a series of protein biomarker panels aimed at various therapeutic areas (PM 3/18/2011).

In November 2011, citing lower than expected sales in its biomarker and testing business, the company entered a convertible loan agreement with Alpha 4 Concepts for the provision of additional funding of £650,000 ($1.04 million) (PM 11/4/2011).

That loan agreement ends on Oct. 31.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.